Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 3Glioblastoma 3Small Cell Lung Carcinoma 1Recurrence 1Prostatic Neoplasms 1Leukemia, Myeloid, Acute 1Leiomyosarcoma 1Ichthyosis, X-Linked 1Glioma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Doxorubicin 6Specimen Handling 5Radiotherapy 3Radiation 3Nivolumab 3Magnetic Resonance Spectroscopy 3Gemcitabine 3Biopsy 3pembrolizumab 2liposomal doxorubicin 2eribulin 2Ifosfamide 2toripalimab 1talimogene laherparepvec 1rucaparib 1ribociclib 1regorafenib 1peposertib 1pazopanib 1olaratumab 1olaparib 1lenvatinib 1futibatinib 1durvalumab 1dinutuximab 1cemiplimab 1cediranib 1cabozantinib 1avelumab 1anlotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leiomyosarcoma × ADI PEG20 × 1 year × Clear all
NCT05712694 2026-04-20

Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)

Polaris Group

Phase 3 Recruiting
300 enrolled
Sarcoma

Leiomyosarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡